Terms: = Thyroid cancer AND ELK4, SAP1, 2005, ENSG00000158711, P28324 AND Treatment
245 results:
1. Primary thyroid lymphoma: a case series.
Sakhri S; Zemni I; Ayadi MA; Kamoun S; Chargui R; Ben Dhiab T
J Med Case Rep; 2024 Feb; 18(1):108. PubMed ID: 38395921
[TBL] [Abstract] [Full Text] [Related]
2. Global research trends and prospects related to tumor microenvironment within Triple Negative Breast cancer: a bibliometric analysis.
Li P; Li J; Tong X; Xiao Z; Diao W; Zhong C; Zhou J; Wu W
Front Immunol; 2023; 14():1261290. PubMed ID: 38111580
[TBL] [Abstract] [Full Text] [Related]
3. Radioactive iodine therapy for follicular thyroid cancer: a 15 years follow-up study of Chinese patients.
Shi H; Yang B; Feng JI; Li JH; Cheng X; Li YJ; Fu Y; Xu XD; Qian LH; Tang LJ; Liu W
Nucl Med Commun; 2024 Mar; 45(3):169-174. PubMed ID: 38095140
[TBL] [Abstract] [Full Text] [Related]
4. Cardiorespiratory fitness and BMI measured in youth and 5-year mortality after site-specific cancer diagnoses in men-A population-based cohort study with register linkage.
Onerup A; Mehlig K; Ekblom-Bak E; Lissner L; Börjesson M; Åberg M
Cancer Med; 2023 Oct; 12(19):20000-20014. PubMed ID: 37732468
[TBL] [Abstract] [Full Text] [Related]
5. The impact of lymph node ratio on disease recurrence in papillary thyroid microcarcinoma.
de Jong MC; Mahipal M; Ngiam KY; Tan WB; Yang SP; Parameswaran R
Ann R Coll Surg Engl; 2023 Sep; 105(7):632-638. PubMed ID: 37652084
[TBL] [Abstract] [Full Text] [Related]
6. Lateral neck dissection for the treatment of synchronous and metachronous lateral neck metastasis of N1b papillary thyroid cancer.
Yun HJ; Lee JS; Lee JS; Kim SM; Chang H; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2023; 14():1166640. PubMed ID: 37424860
[TBL] [Abstract] [Full Text] [Related]
7. Active Surveillance Outcomes of Patients with Low-Risk Papillary thyroid Microcarcinoma According to Levothyroxine treatment Status.
Yamamoto M; Miyauchi A; Ito Y; Fujishima M; Sasaki T; Kudo T
Thyroid; 2023 Oct; 33(10):1182-1189. PubMed ID: 37310904
[No Abstract] [Full Text] [Related]
8. Bilaterality, not multifocality, is an independent risk factor for recurrence in low-risk papillary thyroid cancer.
Rodriguez Schaap PM; Lin JF; Metman MJH; Dreijerink KMA; Links TP; Bonjer HJ; Nieveen van Dijkum EJM; Dickhoff C; Kruijff S; Engelsman AF
J Natl Cancer Inst; 2023 Sep; 115(9):1071-1076. PubMed ID: 37267155
[TBL] [Abstract] [Full Text] [Related]
9. The 15-year national trends of endocrine cancers incidence among Iranian men and women; 2005-2020.
Balajam NZ; Mousavian AH; Sheidaei A; Gohari K; Tavangar SM; Ghanbari-Motlagh A; Ostovar A; Shafiee G; Heshmat R
Sci Rep; 2023 May; 13(1):7632. PubMed ID: 37164997
[TBL] [Abstract] [Full Text] [Related]
10. Differentiated thyroid cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine treatment.
Chiapponi C; Hartmann MJM; Decarolis B; Simon T; Bruns CJ; Faust M; Schultheis AM; Schmidt M; Alakus H
J Clin Res Pediatr Endocrinol; 2023 Aug; 15(3):257-263. PubMed ID: 36987773
[TBL] [Abstract] [Full Text] [Related]
11. Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies.
Abraham DS; Nguyen TPP; Blank LJ; Thibault D; Gray SL; Hennessy S; Leonard CE; Weintraub D; Willis AW
Neurotherapeutics; 2023 Mar; 20(2):375-388. PubMed ID: 36864331
[TBL] [Abstract] [Full Text] [Related]
12. Impact of the EU Paediatric Medicine Regulation on new anti-cancer medicines for the treatment of children and adolescents.
Vassal G; de Rojas T; Pearson ADJ
Lancet Child Adolesc Health; 2023 Mar; 7(3):214-222. PubMed ID: 36682367
[TBL] [Abstract] [Full Text] [Related]
13. Recombinant or endogenous thyroid-stimulating hormone for radioactive iodine therapy in thyroid cancer: state of knowledge and current controversies.
Coerts HI; de Keizer B; Marlowe RJ; Verburg FA
Eur J Endocrinol; 2023 Feb; 188(2):. PubMed ID: 36655579
[TBL] [Abstract] [Full Text] [Related]
14. Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.
Gao H; Huang J; Dai Q; Su J
Arch Endocrinol Metab; 2023 Mar; 67(2):197-205. PubMed ID: 36651706
[TBL] [Abstract] [Full Text] [Related]
15. Active surveillance is an excellent management technique for identifying patients with progressive low-risk papillary thyroid microcarcinoma requiring surgical treatment.
Fujishima M; Miyauchi A; Ito Y; Kudo T; Noda T; Sano T; Sasaki T; Kishi T; Nakamura T
Endocr J; 2023 Apr; 70(4):411-418. PubMed ID: 36631086
[TBL] [Abstract] [Full Text] [Related]
16. Propensity score matching analysis of adjuvant external-beam radiotherapy for the treatment of papillary thyroid carcinoma with other organ invasions.
Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
Endocrine; 2023 Jun; 80(3):589-599. PubMed ID: 36600104
[TBL] [Abstract] [Full Text] [Related]
17. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
[TBL] [Abstract] [Full Text] [Related]
18. thyroid Lobectomy for Low-Risk 1-4 CM Papillary thyroid cancer is not Associated with Increased Recurrence Rates in the Dutch Population with a Restricted Diagnostic Work-Up.
Lin JF; Rodriguez Schaap PM; Metman MJH; Nieveen van Dijkum EJM; Dickhoff C; Links TP; Kruijff S; Engelsman AF
World J Surg; 2023 May; 47(5):1211-1218. PubMed ID: 36303039
[TBL] [Abstract] [Full Text] [Related]
19. Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment.
Tran TV; Rubino C; Allodji R; Andruccioli M; Bardet S; Diallo I; Dottorini M; Garsi J; Hall P; Henry-Amar M; Lamart S; Le Thai F; Lönn S; Ricard M; Schvartz C; Schlumberger M; Journy N; de Vathaire F
Br J Cancer; 2022 Dec; 127(12):2118-2124. PubMed ID: 36224404
[TBL] [Abstract] [Full Text] [Related]
20. Early post-treatment
Lu HH; Chiu NT; Tsai MH
Cancer Imaging; 2022 Oct; 22(1):59. PubMed ID: 36217182
[TBL] [Abstract] [Full Text] [Related]
[Next]
